2,373
Views
15
CrossRef citations to date
0
Altmetric
Research Article

Surface density of polyarginine influence the size, zeta potential, cellular uptake and tissue distribution of the nanostructured lipid carrier

, , , , , , & show all
Pages 519-526 | Received 15 Oct 2016, Accepted 05 Dec 2016, Published online: 09 Feb 2017

References

  • Alhakamy NA, Dhar P, Berkland CJ. (2016). Charge type, charge spacing, and hydrophobicity of arginine-rich cell-penetrating peptides dictate gene transfection. Mol Pharm 13:1047–57
  • Bhattacharjee S. (2016). DLS and zeta potential – what they are and what they are not? J Control Release 235:337–51
  • Futaki S. (2005). Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv Drug Deliv Rev 57:547–58
  • Futaki S, Suzuki T, Ohashi W, et al. (2001). Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276:5836–40
  • Garg NK, Tyagi RK, Singh B, et al. (2016). Nanostructured lipid carrier mediates effective delivery of methotrexate to induce apoptosis of rheumatoid arthritis via NF-kappaB and FOXO1. Int J Pharm 499:301–20
  • Gautam A, Sharma M, Vir P, et al. (2015). Identification and characterization of novel protein-derived arginine-rich cell-penetrating peptides. Eur J Pharm Biopharm 89:93–106
  • Guterstam P, Madani F, Hirose H, et al. (2009). Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochim Biophys Acta 1788:2509–17
  • Han C, Li Y, Sun M, et al. (2014). Small peptide-modified nanostructured lipid carriers distribution and targeting to EGFR-overexpressing tumor in vivo. Artif Cells Nanomed Biotechnol 42:161–6
  • Joshi AS, Patel HS, Belgamwar VS, et al. (2012). Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: development, optimization and evaluation. J Mater Sci Mater Med 23:2163–75
  • Kang MH, Park MJ, Yoo HJ, et al. (2014). RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells. Eur J Pharm Biopharm 87:489–99
  • Khalil IA, Kogure K, Futaki S, Harashima H. (2006). High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 281:3544–51
  • Khalil IA, Kogure K, Futaki S, Harashima H. (2008). Octaarginine-modified liposomes: enhanced cellular uptake and controlled intracellular trafficking. Int J Pharm 354:39–48
  • Kim HK, Davaa E, Myung CS, Park JS. (2010). Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int J Pharm 392:141–7
  • Lozano MV, Lollo G, Alonso-Nocelo M, et al. (2013). Polyarginine nanocapsules: a new platform for intracellular drug delivery. J Nanoparticle Res 15:1515
  • Lynch I, Salvati A, Dawson KA. (2009). Protein-nanoparticle interactions: what does the cell see? Nat Nanotechnol 4:546–7
  • Müller RH, Radtke M, Wissing SA. (2002). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54:S131–55
  • Nakamura Y, Kogure K, Futaki S, Harashima H. (2007). Octaarginine-modified multifunctional envelope-type nano device for siRNA. J Control Release 119:360–7
  • Oyarzun-Ampuero FA, Goycoolea FM, Torres D, Alonso MJ. (2011). A new drug nanocarrier consisting of polyarginine and hyaluronic acid. Eur J Pharm Biopharm 79:54–7
  • Park K. (2012). Arginine-rich CPPs for improved drug delivery to tumors. J Control Release 159:153
  • Pujals S, Giralt E. (2008). Proline-rich, amphipathic cell-penetrating peptides. Adv Drug Deliv Rev 60:473–84
  • Suhorutsenko J, Oskolkov N, Arukuusk P, et al. (2011). Cell-penetrating peptides, PepFects, show no evidence of toxicity and immunogenicity in vitro and in vivo. Bioconjug Chem 22:2255–62
  • Tiwari R, Pathak K. (2011). Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415:232–43
  • Torchilin VP. (2008). Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 60:548–58
  • Trehin R, Merkle HP. (2004). Chances and pitfalls of cell penetrating peptides for cellular drug delivery. Eur J Pharm Biopharm 58:209–23
  • Tsai M, Lu Z, Wientjes MG, Au JL. (2013). Paclitaxel-loaded polymeric microparticles: quantitative relationships between in vitro drug release rate and in vivo pharmacodynamics. J Control Release 172:737–44
  • Xie F, Ji S, Cheng Z. (2015). In vitro dissolution similarity factor (f2) and in vivo bioequivalence criteria, how and when do they match? Using a BCS class II drug as a simulation example. Eur J Pharm Sci 66:163–72
  • Ye J, Shin MC, Liang Q, et al. (2015). 15 Years of attempts: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting. J Control Release 205:58–69
  • Zhang C, Tang N, Liu X, et al. (2006). siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release 112:229–39
  • Zhang T, Xue X, He D, Hsieh JT. (2015). A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA. Cancer Lett 365:156–65
  • Zhang W, Li X, Ye T, et al. (2013). Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology. Int J Pharm 454:354–66
  • Zhang W, Liu J, Zhang Q, et al. (2014). Enhanced cellular uptake and anti-proliferating effect of chitosan hydrochlorides modified genistein loaded NLC on human lens epithelial cells. Int J Pharm 471:118–26
  • Zhang X, Gan Y, Gan L, et al. (2008). PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer. J Pharm Pharmacol 60:1077–87
  • Zurm, Hlen A, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 45:149–55